All In Biotech

Drug Trial Radar · NCT06533644

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

91

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Apr 14, 2028

Study completion Apr 14, 2028

Sponsor

Lead sponsor
Syncromune, Inc.Industry
Sponsor type
Industry
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • Partial OncolysisProcedure

    Partial tumor oncolysis will be completed by cryolysis.

  • SV-102Drug

    Intratumoral infusion of SV-102

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Immune-related Adverse Reactions (imARs)Time frame: Up to 2 years
  2. Maximum Tolerated DoseTime frame: Up to 48 weeks
  3. Optimal Biologic Dose (OBD)Time frame: Up to 48 weeks
  4. Recommended Phase 2 Dose (RP2D)Time frame: Up to 48 weeks
  5. Objective Response Rate (ORR)Time frame: Up to 2 years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Not yet recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • Arkansas Urology

    Little Rock, Arkansas · Not yet recruiting

  • University of California-Davis

    Sacramento, California · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Not yet recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Not yet recruiting

  • Duly Health

    Lisle, Illinois · Recruiting

  • Wichita Urology

    Wichita, Kansas · Recruiting

  • Willis Knighton

    Shreveport, Louisiana · Not yet recruiting

  • Michigan Institute of Urology

    Troy, Michigan · Recruiting

  • Mercy Hospital

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Northwell Health

    Lake Success, New York · Recruiting

  • NYU Langone

    New York, New York · Recruiting

  • Weill Cornell

    New York, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Not yet recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Houston Metro Urology

    Houston, Texas · Not yet recruiting

  • Summit Urology

    Murray, Utah · Not yet recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.